Senior Scientist - Team Lead Celanese Florence, Kentucky
Although traditional drug delivery is the most frequent path taken for an initial product launch, it often overlooks the enhanced efficacy that could be achieved through drug delivery optimization from more unconventional means. Some of these unconventional options include long-acting, sustained drug delivery of many therapeutics as well as a localized delivery approach. Both continue to hold strong interest to help maximize treatment outcomes across many disease indications.
Despite interest in these areas, the sustained delivery of biologics and RNA continue to present formulation challenges, including stability, potency, drug release rates and manufacturing. Drug-eluting solid implants are a promising solution to address these challenges, providing tunable release of a wide range of drugs molecules for both systemic and localized delivery.
Celanese has developed a polymeric drug delivery platform based on ethylene-vinyl acetate (VitalDose® EVA) for the sustained delivery of not only small molecules and peptides but also biologics and RNA. High levels of tunability can be achieved based on various attributes including drug loading, implant design and polymer selection. This technology platform can provide systemic as well as localized drug delivery which may be suitable for multiple therapy areas including oncology, CNS disorders, ophthalmology, rare diseases, endocrinology and women’s health.
Learning Objectives:
Understand the value of a non-traditional dosage form that can be achieved through the use of VitalDose® EVA
Use tunability levers to achieve a targeted release profile using ethylene vinyl acetate as the drug release system
Apply formulation strategies for the stability and release of small molecules, peptides, RNA and mAbs